In PNAS this week: common, not rare ERAP1 variants linked to ankylosing spondylitis, recurrent VAV1 mutations in peripheral T-cell lymphoma, and more.
Roche has licensed and plans to commercialize the circulating tumor DNA technology, which the Stanford researchers dubbed CAPP-seq.
The companies will initially focus on developing a companion diagnostic for Merck's investigational B cell lymphoma drug M7583.
The company said its HTG EdgeSeq system and EdgeSeq Diffuse Large B-Cell Lymphoma Cell of Origin Assay may now be distributed in the EU.
Researchers used single-cell sequencing to uncover karyotype heterogeneity within mouse and human cancers and predicted that it might be linked to outcomes.
Truncations to PD-L1's 3' untranslated region were detected in a variety of tumor types, apparently increasing expression of the gene and decreasing immune response to it.
Early results of a study suggest at least some recurrent gene mutations differ by breed for dogs affected by B-cell and/or T-cell lymphomas.
Independent analyses on dozens of tumor-normal Sézary syndrome pairs points to frequent alterations in signaling, cell cycle, and epigenetic pathways.
Researchers have sequenced and analyzed more than 50 feral and domestic cats in search of genetic variants involved in specific physical features and forms of disease.
In Science this week: ancient Ethiopian genome indicates greater Eurasian backflow into Africa, sequencing to diagnose cutaneous T cell lymphoma, and more.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.